153 related articles for article (PubMed ID: 29113288)
1. HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Hideshima T; Mazitschek R; Qi J; Mimura N; Tseng JC; Kung AL; Bradner JE; Anderson KC
Oncotarget; 2017 Oct; 8(46):80109-80123. PubMed ID: 29113288
[TBL] [Abstract][Full Text] [Related]
2. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
3. HDAC6 inhibitor WT161 induces apoptosis in retinoblastoma cells and synergistically interacts with cisplatin.
Sun J; Qian X; Zhang F; Tang X; Ju C; Liu R; Zhou R; Zhang Z; Lv XB; Zhang C; Huang G
Transl Cancer Res; 2019 Dec; 8(8):2759-2768. PubMed ID: 35117033
[TBL] [Abstract][Full Text] [Related]
4. Targeting the 'garbage-bin' to fight cancer: HDAC6 inhibitor WT161 has an anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.
Sergi CM
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34323266
[TBL] [Abstract][Full Text] [Related]
5. HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.
Sun J; Wu W; Tang X; Zhang F; Ju C; Liu R; Liang Y; Yu B; Lv B; Guo Y; Zeng D; Tao X; Wang M; Zhang Z; Zhang C; Lv XB
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33860796
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
7. Nuclear Receptors Are Differentially Expressed and Activated in KAIMRC1 Compared to MCF7 and MDA-MB231 Breast Cancer Cells.
Nehdi A; Ali R; Alhallaj A; Alzahrani H; Samman N; Mashhour A; Baz O; Barhoumi T; Alghanem B; Khan A; Alriyees L; Boudjelal M
Molecules; 2019 May; 24(11):. PubMed ID: 31141879
[TBL] [Abstract][Full Text] [Related]
8. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Hui KF; Chiang AK
Int J Cancer; 2014 Dec; 135(12):2950-61. PubMed ID: 24771510
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
[TBL] [Abstract][Full Text] [Related]
10. Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Hideshima T; Mazitschek R; Qi J; Mimura N; Tseng JC; Kung AL; Bradner JE; Anderson KC
Oncotarget; 2021 Aug; 12(17):1736. PubMed ID: 34434504
[TBL] [Abstract][Full Text] [Related]
11. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
12. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Yu S; Cai X; Wu C; Liu Y; Zhang J; Gong X; Wang X; Wu X; Zhu T; Mo L; Gu J; Yu Z; Chen J; Thiery JP; Chai R; Chen L
Int J Biol Sci; 2017; 13(4):505-517. PubMed ID: 28529458
[TBL] [Abstract][Full Text] [Related]
13. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
[TBL] [Abstract][Full Text] [Related]
14. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
15. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
16. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
[TBL] [Abstract][Full Text] [Related]
17. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
Amengual JE; Johannet P; Lombardo M; Zullo K; Hoehn D; Bhagat G; Scotto L; Jirau-Serrano X; Radeski D; Heinen J; Jiang H; Cremers S; Zhang Y; Jones S; O'Connor OA
Clin Cancer Res; 2015 Oct; 21(20):4663-75. PubMed ID: 26116270
[TBL] [Abstract][Full Text] [Related]
18. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
19. HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation.
Sun S; Zhang Y; Zheng J; Duan B; Cui J; Chen Y; Deng W; Ye B; Liu L; Chen Y; Du J; Gu L
Cell Death Dis; 2018 Sep; 9(9):929. PubMed ID: 30206202
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
Komatsu S; Moriya S; Che XF; Yokoyama T; Kohno N; Miyazawa K
Biochem Biophys Res Commun; 2013 Jul; 437(1):41-7. PubMed ID: 23792097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
